Last updated: September 25, 2026
Dianeal Low Calcium With Dextrose 4.25% in Plastic Container is a Baxter-developed peritoneal dialysis solution used in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. Its commercial outlook is tied to the growth of home dialysis, the number of patients with end-stage kidney disease, manufacturing capacity for sterile solutions, and Baxter's separation of its Kidney Care business into Vantive. Product-level revenue is not separately disclosed, so financial analysis must rely on broader peritoneal dialysis and Kidney Care disclosures.
What is Dianeal Low Calcium With Dextrose 4.25%?
Dianeal is a sterile dialysis solution containing dextrose as the osmotic agent and electrolytes used for peritoneal dialysis. The 4.25% dextrose formulation produces higher ultrafiltration than lower-dextrose formulations and is generally used when greater fluid removal is required.
| Attribute |
Product profile |
| Product |
Dianeal Low Calcium With Dextrose 4.25% in Plastic Container |
| Manufacturer historically associated with product |
Baxter Healthcare Corporation |
| Current business context |
Kidney Care assets transferred to Vantive after Baxter's divestiture |
| Dosage form |
Sterile peritoneal dialysis solution |
| Route |
Intraperitoneal |
| Primary use |
Continuous ambulatory and automated peritoneal dialysis |
| Osmotic agent |
Dextrose, 4.25% |
| Calcium profile |
Low-calcium formulation |
| Container |
Flexible plastic container |
| Prescription status |
Prescription medical product |
| Product category |
Peritoneal dialysis solution |
| Primary market |
Renal replacement therapy and home dialysis |
The product is administered through a peritoneal dialysis system. It is not an oral pharmaceutical and does not compete primarily through physician prescribing preferences in the same way as conventional medicines. The principal commercial variables are dialysis modality, installed equipment, supply logistics, patient retention, reimbursement and manufacturing reliability.
How large is the peritoneal dialysis market?
The addressable market is established but smaller than the hemodialysis market. Peritoneal dialysis is a home-based therapy and requires recurring deliveries of solution, transfer sets, tubing and related consumables.
The U.S. end-stage kidney disease population exceeds 800,000 patients, with dialysis accounting for the majority of cases. Home dialysis represents a meaningful but minority share of dialysis treatment. Internationally, peritoneal dialysis penetration varies sharply by country because of reimbursement, infrastructure, physician training, home suitability, infection management and availability of dialysis fluid.
Key market drivers include:
- Growth in the end-stage kidney disease population.
- Greater use of home dialysis.
- Government programs supporting home treatment.
- Demand for lower-cost alternatives to in-center hemodialysis.
- Expansion of dialysis services in emerging markets.
- Recurring consumable demand after patient initiation.
The market has a high recurring-revenue component. A patient who remains on peritoneal dialysis can require multiple solution bags per day, although actual usage depends on the prescription, modality, dwell schedule, body size, residual kidney function and fluid status.
What is the financial trajectory of Dianeal?
No public filing reports revenue, gross margin or operating profit for Dianeal Low Calcium With Dextrose 4.25% as an individual stock-keeping unit. Baxter historically reported its Kidney Care business at segment level rather than disclosing revenue by individual dialysis solution, concentration or container configuration.
The product's financial trajectory therefore follows four broader factors:
| Financial factor |
Effect on Dianeal |
| Patient volume |
Increases recurring solution demand |
| Home dialysis adoption |
Expands the peritoneal dialysis patient base |
| Product mix |
Favors higher-value formulations and complete therapy systems |
| Manufacturing utilization |
Improves margins when sterile-fluid plants operate at higher capacity |
| Supply interruptions |
Can reduce sales, increase costs and damage customer retention |
| Reimbursement |
Determines provider and patient access |
| Input costs |
Affect plastic, dextrose, electrolytes, labor, energy and freight expenses |
| Business ownership |
Shifts commercial reporting from Baxter to Vantive |
Baxter's Kidney Care business was sold to Carlyle for approximately $3.8 billion in a transaction that created Vantive as a standalone kidney-care company. The transaction closed in 2024, subject to customary conditions and regulatory processes (Baxter International, 2024). Dianeal is therefore commercially relevant to Vantive's recurring home-dialysis portfolio rather than to Baxter's continuing consolidated product portfolio.
The main financial conclusion is that Dianeal is a mature, recurring-use hospital and home-care product. Revenue growth is more likely to track patient and modality expansion than price-led innovation. Margin performance depends heavily on plant throughput, supply-chain reliability and the economics of the broader peritoneal dialysis system.
Who manufactures and sells competing peritoneal dialysis solutions?
The principal competitive structure is concentrated. Baxter has historically been the leading global supplier of peritoneal dialysis solutions and related equipment. Fresenius Medical Care is the other major integrated dialysis company, with peritoneal dialysis solutions, cyclers and clinical services in multiple markets. Regional manufacturers and local suppliers compete in selected countries.
| Company |
Relevant competitive position |
| Vantive |
Former Baxter Kidney Care business; peritoneal dialysis solutions, cyclers and consumables |
| Fresenius Medical Care |
Peritoneal dialysis solutions, equipment and dialysis services |
| Regional manufacturers |
Country-specific or hospital-focused solution supply |
| Contract and local suppliers |
May compete where regulatory approvals and local manufacturing support entry |
Competition is often system-based rather than molecule-based. A supplier with a cycler, patient training program, technical-support network and established distribution channel has advantages over a supplier offering only a dialysis bag.
What FDA regulatory status applies to Dianeal?
Dianeal is regulated as a prescription dialysis solution. Its regulatory profile is based on product approval, manufacturing compliance, labeling and sterile-product controls rather than on the exclusivity framework used for many new chemical entities.
The FDA-approved labeling covers the product's composition, indications, administration, contraindications, warnings, adverse reactions and storage requirements. Important clinical risks include peritonitis, catheter-related complications, electrolyte disturbances, fluid imbalance, hyperglycemia and problems caused by excessive ultrafiltration (DailyMed, n.d.).
The product's commercial continuity depends on:
- FDA-compliant sterile manufacturing;
- validated container and seal integrity;
- consistent electrolyte and dextrose concentrations;
- reliable packaging and shipping;
- adequate labeling and lot controls;
- continuity of distribution to home patients and dialysis providers.
What is the Orange Book status of Dianeal?
Dianeal is not commercially positioned like a conventional branded small-molecule drug protected by a dense Orange Book patent estate. The product is a dialysis solution with established active ingredients, a defined composition and a sterile container system.
The principal barriers to competition are likely to be:
- FDA approval of the finished solution;
- sterile manufacturing capability;
- container and packaging validation;
- dialysis-provider contracts;
- home-patient training and support;
- reliable supply of large-volume products;
- regulatory compliance at high-volume production sites.
No product-specific patent numbers, expiration dates or Paragraph IV litigation should be treated as material to Dianeal without a current FDA Orange Book review and a patent litigation search covering the exact formulation and container configuration. Product-level patent protection is not the main commercial moat for this mature dialysis solution.
Are Paragraph IV challenges or generic-entry risks material?
Paragraph IV litigation is generally less central for Dianeal than for a conventional branded tablet or injectable with listed patents. A competing manufacturer could pursue an abbreviated or other applicable FDA pathway, but the commercial challenge would be manufacturing and distribution rather than simply invalidating a patent.
Generic-entry risk exists in principle but is constrained by:
- The need for validated large-volume sterile production.
- The cost of dedicated filling and packaging equipment.
- The operational consequences of supply failure.
- The importance of provider and home-care logistics.
- The need to maintain consistent product quality across high-volume batches.
- The limited number of qualified global suppliers.
A lower-priced entrant could gain share in hospital or institutional channels, particularly where tenders are used. Substitution is slower in home dialysis because patients and providers rely on established delivery schedules, equipment compatibility, training and clinical protocols.
What patents protect Dianeal and its formulation?
The strongest intellectual-property issues are more likely to relate to dialysis systems, cyclers, connectors, packaging, manufacturing processes and delivery protocols than to the basic Dianeal solution composition.
Potentially relevant IP categories include:
| IP category |
Commercial relevance |
| Solution composition |
Limited protection for mature electrolyte and dextrose formulations |
| Container design |
May protect packaging, ports, seals or compatibility |
| Cycler technology |
Can reinforce supplier lock-in for automated peritoneal dialysis |
| Connectors and transfer sets |
May support infection-control and system compatibility |
| Manufacturing methods |
Can protect process controls and production efficiency |
| Treatment protocols |
May cover automated dosing or fluid-management methods |
| Trademarks |
Protect Dianeal brand identity and source designation |
The 4.25% dextrose concentration is a standard dialysis-solution specification rather than an apparent product innovation with an obvious new-drug patent life. A current patent landscape would need to distinguish expired legacy patents from active patents covering containers, connectors, cyclers and manufacturing processes.
How do formulation and clinical-use risks affect demand?
The 4.25% formulation is clinically useful when higher fluid removal is needed, but frequent or prolonged use can increase risks associated with high glucose exposure and excessive ultrafiltration. The product must be selected within an individualized dialysis prescription.
Dianeal's demand is therefore not independent of the broader solution portfolio. Patients may use multiple dextrose concentrations during the same treatment period. A supplier can retain the account even when volume shifts between 1.5%, 2.5% and 4.25% formulations.
Competitive differentiation can arise from:
- low-calcium and standard-calcium options;
- icodextrin-based alternatives for long dwells;
- amino-acid solutions in selected patients;
- cycler compatibility;
- bag design and ease of connection;
- delivery reliability;
- support for automated peritoneal dialysis.
What supply-chain events affect Dianeal's market outlook?
Sterile dialysis fluids are vulnerable to manufacturing disruptions because production is concentrated and replacement capacity is limited. Baxter experienced significant operational pressure from supply-chain disruptions and a 2024 cyber incident affecting hospital products and manufacturing operations. Baxter disclosed that the incident affected operations and required remediation, although the precise effect on Dianeal revenue was not separately reported (Baxter International, 2024).
The 2024 separation of Kidney Care also changes supply-chain governance. Vantive must operate manufacturing, procurement, distribution and regulatory functions independently from Baxter's continuing businesses. That creates execution risk during the transition but may allow the kidney-care portfolio to receive more focused capital allocation.
What generic launch scenarios exist for Dianeal?
Scenario 1: Stable incumbent supply
Vantive maintains manufacturing capacity and service levels. Dianeal retains its installed base, with volume growing in line with peritoneal dialysis adoption and patient counts.
Scenario 2: Contract-driven price erosion
Regional or multinational competitors win hospital and clinic tenders with lower prices. Dianeal remains important in home care but experiences lower net pricing in institutional channels.
Scenario 3: Supply disruption
A plant outage, quality event or distribution failure causes temporary substitution. Customers may permanently qualify alternative suppliers, reducing the incumbent's share even after supply is restored.
Scenario 4: Modality shift
Growth in home dialysis supports peritoneal dialysis, but patients may shift between peritoneal dialysis and home hemodialysis. The impact on Dianeal depends on the relative expansion of each modality.
How strong is the commercial moat?
Dianeal's commercial moat is moderate to strong in the near term, but it is operational rather than patent-driven.
Strengths include:
- recurring consumption;
- established clinical use;
- integration with dialysis equipment;
- patient and provider familiarity;
- high manufacturing barriers;
- supply-chain scale;
- regulatory complexity.
Weaknesses include:
- limited product differentiation;
- mature formulation technology;
- potential tender-based price pressure;
- dependence on sterile production;
- exposure to manufacturing and logistics failures;
- lack of publicly disclosed product-level financial transparency.
The most important competitive asset is the full peritoneal dialysis platform. Dianeal alone has less defensibility than the combination of solution bags, cyclers, transfer sets, patient services and supply distribution.
Key Takeaways
- Dianeal Low Calcium With Dextrose 4.25% is a mature peritoneal dialysis solution used for higher ultrafiltration needs.
- Product-specific revenue and profit are not publicly disclosed.
- Its market is driven by end-stage kidney disease prevalence, home dialysis adoption and recurring solution consumption.
- Baxter historically owned the relevant Kidney Care business; that business was transferred to Vantive following the 2024 divestiture.
- Orange Book and Paragraph IV risks are less important than sterile manufacturing, regulatory compliance and distribution capacity.
- The main competitive threat is substitution by Fresenius Medical Care or regional suppliers during price tenders or supply disruptions.
- The commercial moat is based on integrated dialysis systems and supply reliability, not a strong composition-of-matter patent estate.
- Financial performance should be assessed through Vantive's Kidney Care disclosures, peritoneal dialysis volume, manufacturing utilization and supply-chain execution.
FAQs About Dianeal Low Calcium With Dextrose 4.25%
Is Dianeal 4.25% dextrose still commercially important?
Yes. It remains relevant for patients requiring higher ultrafiltration, although its use is balanced against the clinical risks of high-glucose dialysis solutions.
Does Dianeal have biosimilar competition?
No. Biosimilar rules apply to biological products. Dianeal is a sterile dialysis solution, so competition would involve pharmaceutical-equivalent or therapeutically substitutable dialysis products rather than biosimilars.
Who owns Dianeal after Baxter's Kidney Care divestiture?
Baxter's former Kidney Care business was transferred to Vantive in connection with Baxter's sale to Carlyle. Commercial ownership and operational responsibility should be evaluated through current Vantive disclosures.
Can a generic manufacturer launch a competing Dianeal solution?
A competing manufacturer could seek FDA authorization, but it would need validated sterile production, packaging controls, regulatory approval and reliable distribution. Manufacturing capacity is a larger barrier than conventional patent litigation.
What is the biggest financial risk for Dianeal?
The largest risks are supply interruption, manufacturing remediation, price pressure in institutional contracts and slower growth in peritoneal dialysis relative to other renal-replacement modalities.
References
-
Baxter International Inc. (2024). Annual report and Form 10-K for the year ended December 31, 2023. Baxter International Inc.
-
Baxter International Inc. (2024). Baxter announces completion of sale of Kidney Care business to Carlyle. Baxter International Inc.
-
DailyMed. (n.d.). Dianeal low calcium with dextrose 4.25% peritoneal dialysis solution: Prescribing information. U.S. National Library of Medicine.
-
U.S. Renal Data System. (2024). 2024 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
